Go6976 is a novel and potent inhibitor of JAK2 and JAK3 tyrosine kinases both in vitro and in cellular assays

被引：0
|
作者：
Grandage, VL [1 ]
Linch, DC [1 ]
Khwaja, A [1 ]
机构：
[1] UCL Royal Free & UCL Med Sch, Dept Haematol, London, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2005年 / 129卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15
引用
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [1] Go6976, a novel and potent inhibitor of JAK2 and JAK3, reduces constitutive STAT activity and induces apoptosis in myeloid leukaemia and anaplastic lymphoma cells
    Grandage, VL
    Linch, DC
    Khwaja, A
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 40 - 40
  • [2] Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells
    Grandage, Victoria L.
    Everington, Tamara
    Linch, David C.
    Khwaja, Asim
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 135 (03) : 303 - 316
  • [3] Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor
    Alfonso Quintás-Cardama
    Taghi Manshouri
    Zeev Estrov
    David Harris
    Ying Zhang
    Amos Gaikwad
    Hagop M. Kantarjian
    Srdan Verstovsek
    Investigational New Drugs, 2011, 29 : 818 - 826
  • [4] Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor
    Quintas-Cardama, Alfonso
    Manshouri, Taghi
    Estrov, Zeev
    Harris, David
    Zhang, Ying
    Gaikwad, Amos
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 818 - 826
  • [5] In vitro and in vivo characterization of a novel Jak3 tyrosine kinase inhibitor
    Sills, M.
    Appell, K.
    Bohnstedt, A.
    Kimble, E.
    Kingsbury, C.
    Lin, T.
    Ohlmeyer, M.
    Quadros, E.
    Webb, M.
    INFLAMMATION RESEARCH, 2006, 55 : S118 - S119
  • [6] In Vitro and in Vivo Inhibition of JAK2 Signaling by Potent and Selective JAK2 Inhibitor
    Markovtsov, Vadim
    Tonkin, Elizabeth
    Fang, Shuling
    Liu, Chiang
    Gelman, Marina
    Lang, Wayne
    Romero, Jason
    McLaughlin, John
    Bhamidipati, Somasekhar
    Clough, Jeffrey
    Singh, Rajinder
    Low, Caroline
    Reitsma, Andrea
    Taylor, Vanessa
    Siu, Stacey
    Park, Gary
    Sweeney, David
    Pine, Polly
    Torneros, Allan
    Clemens, George
    Duan, Matt
    Daniel, Ruby
    Payan, Donald
    Holland, Sacha
    Hitoshi, Yasumichi
    BLOOD, 2008, 112 (11) : 1276 - 1276
  • [7] Development of novel and potent inhibitors of JAK2: Structure activity relationship studies for optimiziation of JAK2 potency while minimizing JAK3 activity
    McPherson, Andrew
    Cao, Jianguo
    Chow, Chun
    Fine, Richard
    Hood, John
    Kang, Xinshan
    Klebansky, Boris
    Lohse, Dan
    Mak, Chi Ching
    Noronha, Glenn
    Pathak, Ved P.
    Renick, Joel
    Soll, Richard
    Zeng, Binqi
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 779 - 779
  • [8] Selective Downregulation of JAK2 and JAK3 by an ATP-Competitive pan-JAK Inhibitor
    Field, S. Denise
    Arkin, Jacob
    Li, Jing
    Jones, Lyn H.
    ACS CHEMICAL BIOLOGY, 2017, 12 (05) : 1183 - 1187
  • [9] JAK2, A 3RD MEMBER OF THE JAK FAMILY OF PROTEIN TYROSINE KINASES
    HARPUR, AG
    ANDRES, AC
    ZIEMIECKI, A
    ASTON, RR
    WILKS, AF
    ONCOGENE, 1992, 7 (07) : 1347 - 1353
  • [10] In vitro and in vivo characterization of the potent and selective JAK2 inhibitor
    Markovtsov, Vadim
    Tonkin, Elizabeth
    Fang, Shuling
    Liu, Chian
    Gelman, Marina
    Lang, Wayne
    McLaughlin, John
    Bhamidipati, Sohasekhar
    Clough, Jeffrey
    Singh, Rajinder
    Low, Caroline
    Reitsma, Andrea
    Park, Gary
    Sweeney, David
    Pine, Polly
    Torneros, Allan
    Clemens, George
    Duan, Matt
    Payan, Donald
    Holland, Sacha
    Hitoshi, Yasumichi
    CANCER RESEARCH, 2009, 69
12345